Login Register
English
0

Cart

$ 0
OR
Catalog no Product name Protocol name IF Magazine title
KTE4072 Granzyme K, Regulated by the N6-Methyladenosine Methyltransferase Wilms’ tumor 1-associate protein, Enhances Myocardial Infarction Injury.(KTE4072-2.600) 2.600 DNA and Cell Biology
KTE4073 Granzyme K, Regulated by the N6-Methyladenosine Methyltransferase Wilms’ tumor 1-associate protein, Enhances Myocardial Infarction Injury.(KTE4073-2.600) 2.600 DNA and Cell Biology
KTE6011 EliKine™ Human IFN-γ ELISA Kit In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype.(KTE6011-4.700) 4.700 International Immunopharmacology 
KTE6011 EliKine™ Human IFN-γ ELISA Kit Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response.(KTE6011-10.600) 10.600  Journal for Immunotherapy of Cancer 
KTE6013 EliKine™ Human IL-1β ELISA Kit Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis.(KTE6013-10.500) 10.500 Pharmacological Research 
KTE6013 EliKine™ Human IL-1β ELISA Kit Modulation of secretory factors by lipofundin contributes to its anti‑neuroinflammatory effects.(KTE6013-2.300) 2.300 Experimental and Therapeutic Medicine 
KTE6013 EliKine™ Human IL-1β ELISA Kit Mangiferin represses inflammation in macrophages under a hyperglycemic environment through Nrf2 signaling.(KTE6013-4.900) 4.900 International journal of molecular sciences 
KTE6014 EliKine™ Human IL-2 ELISA Kit Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response.(KTE6014-10.600) 10.600 Journal for Immunotherapy of Cancer 
KTE6015 EliKine™ Human IL-4 ELISA Kit In human CD4+ T-Cells, omeprazole suppresses proliferation, downregulates V-ATPase, and promotes differentiation toward an autoimmunity-favoring phenotype.(KTE6015-4.700) 4.700 International Immunopharmacology 
KTE6017 EliKine™ Human IL-6 ELISA Kit The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities.(KTE6017-10.100) 10.100 Cancer Letters